Literature DB >> 17889964

Infantile bullous pemphigoid treated with intravenous immunoglobulin therapy.

Nobuyuki Sugawara1, Yayoi Nagai, Yoichiro Matsushima, Kumi Aoyama, Osamu Ishikawa.   

Abstract

A 3-month-old boy presented with a 2-week history of rapidly spreading skin rashes. Physical examination revealed generalized urticarial plaques with tense bullae and small vesicles. Histologic examination and immunofluorescence established the diagnosis of bullous pemphigoid. The disease was resistant to conventional therapies with the combination of corticosteroids, dapsone, and erythromycin. Finally, intravenous immunoglobulin therapy brought about a remarkable improvement. We suggest that intravenous immunoglobulin therapy is a valuable treatment option for intractable bullous pemphigoid in infants as well as in adults.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17889964     DOI: 10.1016/j.jaad.2007.08.005

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

Review 1.  The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature.

Authors:  Soheil Tavakolpour
Journal:  J Res Med Sci       Date:  2016-06-14       Impact factor: 1.852

2.  Three case reports of post immunization and post viral Bullous Pemphigoid: looking for the right trigger.

Authors:  Luca Baroero; Paola Coppo; Laura Bertolino; Stefano Maccario; Francesco Savino
Journal:  BMC Pediatr       Date:  2017-02-23       Impact factor: 2.125

3.  Two infants with blistering rashes originating on acral sites as a presenting sign of infantile bullous pemphigoid.

Authors:  Brent Folsom; Tom Raisanen; Milad Eshaq
Journal:  JAAD Case Rep       Date:  2020-04-18

4.  Bullous pemphigoid in infants: characteristics, diagnosis and treatment.

Authors:  Agnes Schwieger-Briel; Cornelia Moellmann; Birgit Mattulat; Franziska Schauer; Dimitra Kiritsi; Enno Schmidt; Cassian Sitaru; Hagen Ott; Johannes S Kern
Journal:  Orphanet J Rare Dis       Date:  2014-12-10       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.